World's First RSV Vaccine, GSK Arexvi Begins Domestic Administration

[Financial News] Korea GSK announced on the 29th that it has started administering its respiratory syncytial virus (RSV) vaccine Arexvi. As a result, Arexvi vaccination has become available at hospitals and clinics nationwide from early June.
The world's first RSV vaccine, Arexvi, was approved by the Ministry of Food and Drug Safety in December last year for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults over 60.
RSV infections can occur at any time of the year. Adults over 60 and those with underlying conditions such as heart or lung diseases can develop severe complications like pneumonia if infected with RSV, making vaccination important for prevention.
Arexvi is administered as a 0.5 mL intramuscular injection. Clinical studies have shown that after a single dose, the RSV-LRTD prevention effect in adults over 60 during the first RSV season was 82.6%, and 94.6% in those with one or more comorbidities.
Additionally, it has been shown that Arexvi maintains a significant preventive effect over three seasons with a single dose.

vrdw88@fnnews.com Kang Jung-mo Reporter